Marco, M., Daniela, T., Marianna, A., Offer, A., D, A.S., Antoni, B.G., Michael, B., Javed, B., Ovidiu, C., Gerasimos, F., Finn, G., A, J.E., Carlos, K.J., Brenda, M., C, P.M., Piotr, P., Amina, R., Arsen, R., Francois, R., . . . Giuseppe, R. (2025). SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.. ESC heart failure. https://doi.org/10.1002/ehf2.15408
Marco M, Daniela T, Marianna A, Offer A, D AS, Antoni BG, et al. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.. ESC heart failure. 2025; doi: 10.1002/ehf2.15408
Marco M, Daniela T, Marianna A, et al. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.[J]. ESC heart failure. 2025. DOI: 10.1002/ehf2.15408.
@article{marco2025,
author = {Metra Marco and Tomasoni Daniela and Adamo Marianna and Amir Offer and Anker Stefan D and Bayes-Genis Antoni and Boehm Michael and Butler Javed and Chioncel Ovidiu and Filippatos Gerasimos and Gustafsson Finn and Jankowska Ewa A and Kaski Juan Carlos and Moura Brenda and Petrie Mark C and Ponikowski Piotr and Rakisheva Amina and Ristic Arsen and Roubille Francois and Savarese Gianluigi and Seferovic Petar and van der Meer Peter and Volterrani Maurizio and Coats Andrew J and Chopra Vijay K and Rosano Giuseppe},
title = {SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.},
journal = {ESC heart failure},
year = {2025},
doi = {10.1002/ehf2.15408},
note = {PMID: 40968746},
}
TY - JOUR AU - Metra Marco AU - Tomasoni Daniela AU - Adamo Marianna AU - Amir Offer AU - Anker Stefan D AU - Bayes-Genis Antoni AU - Boehm Michael AU - Butler Javed AU - Chioncel Ovidiu AU - Filippatos Gerasimos AU - Gustafsson Finn AU - Jankowska Ewa A AU - Kaski Juan Carlos AU - Moura Brenda AU - Petrie Mark C AU - Ponikowski Piotr AU - Rakisheva Amina AU - Ristic Arsen AU - Roubille Francois AU - Savarese Gianluigi AU - Seferovic Petar AU - van der Meer Peter AU - Volterrani Maurizio AU - Coats Andrew J AU - Chopra Vijay K AU - Rosano Giuseppe TI - SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI. T2 - ESC heart failure PY - 2025 DO - 10.1002/ehf2.15408 AN - PMID:40968746 ER -
In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF). Further trials showed efficacy of empagliflozin and dapagliflozin in patients with HF with preserved ejection fraction (HFpEF). These results prompted a broadened recommendation for the SGLT2 inhibitors dapagliflozin or empagliflozin across the whole left ventricular ejection fraction (LVEF) spectrum in the 2023 Focused Update of the ESC HF guidelines and in other international guidelines. In SOLOIST-WHF and EMPULSE, sotagliflozin (enrolling only patients with T2DM) and empagliflozin, respectively, were beneficial when initiated at the end or soon after an episode of decompensated HF. Based on these results and on the early appearance of their beneficial effects, the administration of SGLT2 inhibitors should start early in patients hospitalized for acute HF. Analyses after study drug withdrawal in randomized clinical trials have shown that their benefits may decline rapidly after discontinuation, and thus, persistence of treatment is advised. In EMPACT-MI, empagliflozin did not reduce the primary outcome of cardiovascular (CV) death/HF hospitalization but reduced first/recurrent HF hospitalizations. Potential benefits of SGLT2 inhibitors in further specific conditions (i.e., cardiac amyloidosis, grown-up congenital heart disease and paediatric patients with HF) have been reported in observational studies but need confirmation from prospective trials. This scientific statement summarizes current evidence regarding the effects of SGLT2 inhibitors for the prevention and treatment of HF.